Enhancement of tumor growth by drugs with some common molecular actions

Molecular Carcinogenesis

Volumn 16, Issue 2, 1996, Pages 68-76

  LaBella, Frank S ^a   Brandes, Lorne J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Animal models of cancer; Antidepressants; Antihistamine; Cytochrome P450 monooxygenase; Histamine; Polyamines; Tamoxifen; Tumor promotion

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CETIRIZINE; CLOMIFENE; CYTOCHROME P450 OXYGENASE; DOXYLAMINE; FLUOXETINE; HISTAMINE; HYDROXYZINE; LORATADINE; METHAPYRILENE; POLYAMINE; TAMOXIFEN; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; CLINICAL TRIAL; GROWTH STIMULATION; HUMAN; HYPOTHESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR PROMOTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CARCINOGENS; CELL DIVISION; HISTAMINE H1 ANTAGONISTS; HUMANS; NEOPLASMS; STIMULATION, CHEMICAL; STRUCTURE-ACTIVITY RELATIONSHIP; TAMOXIFEN;

ANIMALIA; RODENTIA;

EID: 0030008861     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199606)16:2<68::AID-MC2>3.0.CO;2-J     Document Type: Review

References (91)

1. Brandes LJ, Arron RJ, Bogdanovic RP, et al. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 52:3796-3800, 1992.
2. 1-antihistamines: Predictive in vitro correlates. J Natl Cancer Inst 86:770-775, 1994.
3. Bassukas ID. Effect of amitriptylin on the growth kinetics of two human cancer xenograft lines in nude mice. International Journal of Oncology 4:977-982, 1994.
4. Iishi H, Tatsuta M, Baba M, Taniguchi H. Enhancement by the tricyclic antidepressant, desipramine, of experimental carcinogenesis in rat colon induced by azoxymethane. Carcinogenesis 14:1837-1840, 1993.
5. Wright SC, Zhong J, Larrick JW. Inhibition of apoptosis as a mechanism of tumor promotion. FASEB J 8:654-660, 1994.
6. Friedman MA, Trimble EL, Abrams JS. Tamoxifen: Trials, tribulations, and trade offs. J Natl Cancer Inst 86:478-479, 1994.
7. Harrison JD, Morris DL, Ellis IO, et al. The effect of tamoxifen and estrogen receptor states on survival in gastric carcinoma. Cancer 64:1007-1010, 1989.
8. Rutvuist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87:645-651, 1995.
9. Muhemann K, Cook LS, Weiss NS. The incidence of hepatocellular carcinoma in US white women with breast cancer after the introduction of tamoxifen in 1977. Breast Cancer Res Treat 30:201-204, 1994.
10. Jordan VC. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110:507-517, 1993.
11. LaBella FS. Molecular basis for binding promiscuity of antagonist drugs. Biochem Pharmacol 42:S1-S8, 1991.
12. 1C) that regulate cell proliferation. Advances in Biosciences 89:31-41, 1993.
13. Brandes LJ, Bogdanovik RP, Tong J, Davie JR, LaBella FS. Intracellular histamine and liver regeneration: High affinity binding of histamine to chromatin, low affinity binding to matrix, and depletion of a nuclear storage pool following partial hepatectomy. Biochem Biophys Res Commun 184:840-847, 1992.
14. 3 receptor antagonist, thioperamide, inhibits adrenal steroidogenesis and histamine binding to adrenocortical microsomes and binds to cytochrome P450. Br J Pharmacol 107:161-164, 1992.
15. Saxena SP, McNicol A, Brandes LJ, Becker AB, Gerrard JM. A role for intracellular histamine in collagen-induced platelet aggregation. Blood 75:407-414, 1990.
16. Saxena SP, Brandes LJ, Becker AB, Simons KJ, LaBella FS, Gerrard JM. Histamine is an intracellular messenger mediating platelet aggregation. Science 243:1596-1599, 1989.
17. Brandes LJ, LaBella FS. Histamine and calcium are independently regulated intracellular mediators of lymphocyte mitogenesis. Biochem Biophys Res Commun 182:786-793, 1992.
18. Kroeger EA, Brandes LJ. Evidence that tamoxifen is a histamine antagonist. Biochem Biophys Res Commun 131:750-755, 1985.
19. 1C) in microsomal and nuclear fractions of rat liver. Agents Actions Suppl 33:325-342, 1991.
20. Nebert DW. Proposed role of drug-metabolizing enzymes: Regulation of steady state levels of the ligands that affect growth, homeostasis, differentiation, and neuroendocrine functions. Mol Endocrinol 5:1203-1214, 1991.
21. Guengerich FP. Roles of cytochrome P450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res 48:2946-2954, 1988.
22. Lucier GW. Receptor mediated carcinogenesis. In: Vainio H, Magee P, McGregor D, McMichael AJ (eds). Mechanisms of Carcinogenesis in Risk Identification, International Agency for Research on Cancer, Lyon, pp. 87-112, 1992.
23. Schult-Hermann R. Tumor promotion in the liver. Arch Toxicol 57:147-158, 1985.
24. Lubet RA, Nims RW, Ward JM, Rice JM, Diwan BA. Induction of cytochrome P(450b) and its relationship to liver tumor promotion. Journal of the American College of Toxicology 8:259-268, 1989.
25. Rice JM, Diwan BA, Hu H, Ward JM, Nims RW, Lubet RA. Enhancement of hepatocarcinogenesis and induction of specific cytochrome P450-dependent monooxygenase activities by the barbiturates allobarbital, aprobarbital, pentobarbital, secobarbital and 5-phenyl- and 5-ethylbarbituric acids. Carcinogenesis 15:395-402, 1994.
26. Diwan BA, Henneman JR, Nims RW, Rice JM. Tumor promotion by an anticonvulsant agent, phenytoin, in mouse liver: Correlation with CYP2B induction. Carcinogenesis 14:2227-2231, 1993.
27. Parkinson A, Clement RP, Casciano CN, Cayen MN. Evaluation of loratadine as an inducer of liver microsomal cytochrome P450 in rats and mice. Biochem Pharmacol 43:2169-2180, 1992.
28. Ioannides C, Parke DV. Induction of cytochrome P450 1 as an indicator of potential chemical carcinogenesis. Drug Metab Rev 25:485-501, 1993.
29. Diwan BA, Rice JM, Ward JM. Tumor-promoting activity of benzodiazepine tranquilizers, diazepam and oxazepam, in mouse liver. Carcinogenesis 7:789-794, 1986.
30. Bartsch H, Petruzzelli S, De Flora S, et al. Carcinogen metabolism and DNA adducts in human lung tissues as affected by tobacco smoking or metabolic phenotype: A case-control study on lung cancer patients. Mutat Res 250:103-114, 1991.
31. McLemore TL, Adelberg S, Liu MC, et al. Expression of CYP1A1 gene in patients with lung cancer: Evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 82:1333-1339, 1990.
32. Harris CC. Chemical and physical carcinogenesis: Advances and perspectives for the 1990s. Cancer Res 51:5023S-5044S, 1991.
33. Wrighton SA, Vanden Branden M, Brown TJ, Van Pelt CS, Thomas PE, Shipley LA. Modulation of rat hepatic cytochromes P450 by chronic methapyrilene treatment. Biochem Pharmacol 42:1093-1097, 1991.
34. Iype PT, Bucana CD, Kelley SP. Carcinogenesis by nonmutagenic chemicals: Early response of rat liver cells induced by methapyrilene. Cancer Res 45:2184-2191, 1985.
35. Jounaidi Y, Bonfils C, Perin F, Negishi M, Lange R. Overexpression of a cytochrome P-450 of the 2A family (CYP2A-5) in chemically induced hepatomas from female mice. Eur J Biochem 219:791-798, 1994.
36. Mikulski SM, Viera A, Shogen K. Human tumor cell growth modulatory effects of the AEBS/H(IC)-binding drugs used as single agents and in combination with a novel amphibian oocyte RNase. International Journal of Oncology 2:804-812, 1993.
37. Thomas DB. Do hormones cause breast cancer? Cancer 53:595-604, 1984.
38. Henderson IC. Endocrine therapy of metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC (eds), Breast Diseases. Lippincott, Philadelphia, 1987, pp 398-428.
39. Kuhl PW. Excess-substrate inhibition in enzymology and high-dose inhibition in pharmacology: A reinterpretation. Biochem J 298:171-180, 1994.
40. Yokoyama H, Ishii K, Yanagisawa T, Taira N. An explanation of bell-shaped, dose-positive inotropic effect curves for denopamine in canine right ventricle muscle. J Cardiovasc Pharmacol 14:570-576, 1989.
41. Dixon M, Webb E. Enzymes. Academic Press, New York, 1979, pp. 81-91.
42. Penhoat A, Jaillard C, Saez JM. Corticotropin positively regulates its own receptors and cAMP response in cultured bovine adrenal cells. Proc Natl Acad Sci USA 86:4978-4981, 1989.
43. Delfs JR, Dichter MA. Effects of somatostatin on mammalian cortical neurons in culture: Physiological actions and unusual dose response characteristics. J Neurosci 3:1176-1188, 1983.
44. Changeux JP, Pinset C, Ribera AB. Effects of chlorpromazine and phencyclidine on mouse C2 acetylcholine receptor kinetics. J Physiol 378:497-513, 1986.
45. LaBella FS. Release of thyrotrophin from anterior pituitary in vivo and in vitro by synthetic neurohypophysial peptides. Can J Physiol Pharmacol 42:75-83, 1964.
46. Krass ME, LaBella FS. Thyrotrophin release in vitro: The role of metabolism in the secretory response to vasopressin, oxytocin, and epinephrine. Endocrinology 82:1183-1190, 1968.
47. Schrenk D, Schafer S, Bock KW. 2,3,7,8-tetrachlorodibenzo-p-dioxin as growth modulator in mouse hepatocytes with high and low affinity Ah receptor. Carcinogenesis 15:27-31, 1994.
48. 1-induced hepatocarcinogenesis in the rat. Carcinogenesis 14:663-667, 1993.
49. Horrobin DF, Trosko JE. The possible effect of diazepam on cancer development and growth. Med Hypotheses 7:115-125, 1981.
50. Hirsimaki P, Hirsimaki Y, Nieminen L, Payne BJ. Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogens. Arch Toxicol 67:49-54, 1993.
51. Maenpaa J, Wiebe V, Koester S, et al. Tamoxifen stimulates in vivo growth of drug resistant estrogen receptor negative breast cancer. Cancer Chemother Pharmacol 32:396-398, 1993.
52. Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE. The importance of tamoxifen metabolism in tamoxifen stimulated breast tumor growth. Cancer Chemother Pharmacol 34:89-95, 1994.
53. Zimniski SJ, Warren RC. Induction of tamoxifen dependent rat mammary tumors. Cancer Res 53:2937-2939, 1993.
54. Ahotupa M, Hirsimaki P, Parssinen R, Mantyla E. Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen induced hepatocarcinogenesis in the rat. Carcinogenesis 15:863-868, 1994.
55. Uwagawa S, Tsuda H, Ozaki K, et al. Modifying effects of various chemicals on tumor development in a rat wide-spectrum organ carcinogenesis model. Jpn J Cancer Res 83:812-820, 1992.
56. Chen Z-Y, Liu F, He C-Y, White CC, Eaton DL. Inhibition of cell proliferation by ciprofibrate in glutathione S-transferase P1-1-positive rat hepatic hyperplastic nodules. Cancer Res 54:2622-2629, 1994.
57. Hirose M, Yada H, Hakoi K, Takahashi S, Ito N. Modification of carcinogenesis by α-tocopherol, t-butylhydroquinone, propyl gallate and butylated hydroxytoluene in a rat multi-organ carcinogenesis model. Carcinogenesis 14:2359-2364, 1993.
58. Motohashi N, Gollapudi SR, Emrani J, Bhattiprolu KR. Antitumor properties of phenothiazines. Cancer Invest 9:305-319, 1991.
59. Jones GRN. Cancer therapy: Phenothiazines in an unexpected role. Tumori 71:563-569, 1985.
60. Schleuning M, Brumme V, Wilmanns W. Growth inhibition of human leukemic cell lines by the phenothiazine derivative fluphenazine. Anticancer Res 13:599-602, 1993.
61. Kamath N, Grabowski D, Ford J, Ganapathi R. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype. Br J Cancer 67:1203-1208, 1993.
62. Wang CY, Hayashida S. Enhancement by phenothiazine and 2,5-di-0-acetyl-D-glucosaccharo-(1,4)(6,3)-dilactone of bladder carcinogenicity of N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide in rats. Cancer Lett 24:37-43, 1984.
63. Gierthy JF, Bennett JA, Bradley LM, Cutler DS. Correlation of in vitro and in vivo growth suppression of MCF-7 human breast cancer by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res 53:3149-3153, 1993.
64. Maronpot RR, Foley JF, Takahashi K, et al. Dose response for TCDD promotion of hepatocarcinogenesis in rats initiated with DEN: Histologic, biochemical, and cell proliferation endpoints. Environ Health Perspect 101:634-642, 1993.
65. Moon RC, McCormick DL, Mehta RG. Inhibition of carcinogenesis by retinoids. Cancer Res 43:2469s-2475s, 1983.
66. Shibata M-A, Hirose M, Masuda A, KatoT, Mutai M, Ito N. Modification of BHA forestomach carcinogenesis in rats: Inhibition by diethylmaleate or indomethacin and enhancement by a retinoid. Carcinogenesis 14:1265-1269, 1993.
67. Greenman DL, Morrissey R, Gaylor DW, Allaben WT. Subchronic studies of pyrilamine in B6C3f(1) mice. Journal of the American College of Toxicology 12:337, 1993.
68. Sebzda E, Wallace VA, Mayer J, Yeung RSM, Mak TW, Ohashi PS. Positive and negative thymocyte selection induced by different concentrations of a single peptide. Science 263:1615-1618, 1994.
69. Re G, Badino P, Girardi C, Di Carlo F. Effects of a beta 2-agonist (clenbuterol) on cultured human (CG-5) breast cancer cells. Pharmacol Res 26:377-384, 1992.
70. Tutton PJ, Barkla DH. Influence of inhibitors of serotonin uptake on intestinal epithelium and colorectal cancer. Br J Cancer 46:260-265, 1982.
71. Pinchouk VG, Balitsky KP. Neurotropic pharmacological influences in experimental carcinogenesis. IARC Sci Publ 51:275-284, 1983.
72. von Metzler A, Nitsch C. Monoamine content in rat brain during carcinogenesis and the influence of the CNS drugs piracetam and imipramine. Naturwissenschaften 72:542-543, 1985.
73. Basso AM, Depiante-Depaoli M, Molina VA. Chronic variable stress facilitates tumoral growth: Reversal by imipramine administration. Life Sci 50:1789-1796, 1992.
74. Frussa-Filho R, Monteiro M do C, Soares CGS, Decio RC. Effects of haloperidol, bromocriptine and amphetamine on the development of Ehrlich ascites carcinoma in mice. Pharmacology 45:58-60, 1992.
75. Sauter C. Cytostatic activity of commonly used tricyclic antidepressants. Oncology 46:155-157, 1989.
76. Kon SH. Underestimation of chronic toxicities of food additives and chemicals: The bias of a phantom rule. Med Hypotheses 4:324-339, 1978.
77. Kahlson G, Rosengren E. Histamine formation as related to growth and protein synthesis. In: Blum JJ (ed), Biogenic Amines as Physiological Regulators, Prentice-Hall, Englewood Cliffs, NJ, 1970, pp 223-238.
78. Kalter H. Teratology of the Central Nervous System, University of Chicago Press, Chicago, 1968.
79. Hueper WC. Occupational and Environmental Cancers in the Urinary System, Yale University Press, New Haven, 1969.
80. Rao VR. Binary combination effects of some pharmacologically active chemicals as promoters of tumorigenesis. J Pharm Sci 81:403-407, 1992.
81. World Health Organization. Overall evaluations of carcinogenicity: An updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum. Supplement 7, 1987.
82. Marselos M, Vainio H. Carcinogenic properties of pharmaceutical agents evaluated in the IARC Monographs programme. Carcinogenesis 12:1751-1766, 1991.
83. Brandes LJ, Friesen LA. Can the clinical course of cancer be influenced by non-antineoplastic drugs? Can Med Assoc J 153:561-566, 1995.
84. Epstein SS. Environmental determinants of human cancer. Cancer Res 34:2425-2435, 1974.
85. White L, Giri N, Vowels MR, Lancaster PAL. Neuroectodermal tumours in children born after assisted conception. Lancet 336:1577, 1990.
86. Kobayashi N, Matsui I, Tanimura M, et al. Childhood neuroectodermal tumours and malignant lymphoma after maternal ovulation induction. Lancet 338:955, 1991.
87. Harlow BL, Cramer DW. Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: Evidence from two combined case-control studies (Massachusetts, United States). Cancer Causes Control 6:130-134, 1995.
88. Tomatis L, Aitio A, Wilbourn J, Shuker L. Human carcinogens so far identified. Jpn J Cancer Res 80:795-807, 1989.
89. Gad SC, Burton E, Chengelis CP, et al. Promotional activities of the non-genotoxic carcinogen bemitradine (SC-33643). J Appl Toxicol 12:157-164, 1992.
90. Glauert HP, Pitot HC. Effect of the antihistamine, methapyrilene, as an initiator of hepatocarcinogenesis in female rats. Cancer Lett 46:189-194, 1989.
91. Gilman AG, Goodman LS, Gilman A. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 6 edn. MacMillan Publishing, New York, 1980, p. 369.